- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02872675
The Effects of Prebiotics on Gut Bacterial Parameters, Immune Function & Exercise-Induced Airway Inflammation.
The Effects of HOST-DM059 Prebiotic Supplementation on Gut Bacterial Metabolites, and Markers of Systemic Inflammation in Adults With and Without Hyperpnoea-Induced Bronchoconstriction: A Double-Blind, Placebo-Controlled, Crossover Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current study will investigate the effects of prebiotic supplementation on airway inflammation/bronchoconstriction in adults diagnosed with Asthma/Exercise-Induced Bronchoconstriction (A/EIB). Previous research conducted in adults diagnosed with A/EIB has reported significant improvements in pulmonary function following three weeks of prebiotic supplementation. The significant improvements in pulmonary function were attributed to an attenuation of various markers of airway inflammation, potentially regulated by gut microbiota mediated improvements in systemic immune function.
Prebiotics are a type of non-digestible carbohydrate/dietary fibre that can only be digested by certain beneficial bacteria. During the fermentation of prebiotics, beneficial bacteria produce energy/metabolites that can be used to support a variety of human immune functions, such as reducing the level of airway inflammation that occurs following exposure to relevant triggers (e.g. exercise).
Imbalances and/or deficiencies in gut bacterial composition/metabolic activity have been identified in children/adults diagnosed asthma. However, the potential mechanisms behind prebiotic mediated improvements in the severity of asthma have yet to be investigated.
Participants with and without A/EIB will be allocated two separate nutritional supplements following a double-blind, placebo-controlled design. During the first phase of the nutritional intervention, participants will consume the first supplement (either prebiotic or placebo), for a total duration of four weeks. A two-week wash out period will then be completed before the remaining nutritional supplement is administered for an equal duration.
Analyses of key human/bacterial metabolite concentrations will be carried out alongside assessments of immune and pulmonary function, and intestinal permeability at baseline, and throughout all phases of the nutritional intervention. Current understandings of the role of the gut microbiota in the pathogenesis of A/EIB will be expanded through the investigation of novel pathophysiological mechanisms, helping to inform future therapeutic prospects for asthma.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, Ng11 8NS
- Nottingham Trent University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Be 18-50 years of age at the date of your first visit.
Have a body mass index (BMI) of 18.5-25 kg∙m2 (this will be worked out by the researchers using the participant's height and body weight).
Be physically active (completing 3 or more exercise sessions a week lasting at least 45 minutes each).
Be a non-smoker.
Asthma is defined as Steps 1, 2, or 3 based on British Thoracic Society guidelines.
Asthma sufferers must have a current medication prescription from their GP (e.g. maintenance/reliever inhalers).
In the researcher's opinion, the participant is able and willing to follow all trial requirements.
Exclusion Criteria
Asthma defined as Steps 4 or 5 based on British Thoracic Society guidelines.
Asthma sufferers who do not have a current medication prescription from their GP (e.g. maintenance and reliever inhalers).
Regular consumption of Omega-3 supplements, and/or high levels of Omega-3 intake from food (e.g. consuming more than 1-2 portions of oily fish such as salmon or mackerel a week).
Regularly consume antioxidant supplements.
Standard multivitamin and mineral supplements are acceptable, as long as the product label states the recommended Dietary Reference Values (DRV's).
If a single antioxidant supplement (e.g. Vitamin C), exceeds the recommended daily DRV's this will be checked with the chief investigator.
Take a daily dose of aspirin or other non-steroidal anti-inflammatory drugs such as ibuprofen.
Have consumed prebiotics and/or probiotics, drugs that affect gastrointestinal mobility, or laxatives in the 4 weeks before participation.
Currently taking a daily dose of anti-histamine, which could not be refrained from for 72 hours before each testing session.
Unable to refrain from taking Asthma medication (e.g. maintenance and reliever inhalers) for a prescribed duration before each testing session (e.g. 8-96 hours).
Vegetarian or vegan diet.
Previously diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, or similar respiratory illness.
Participants with asthma that have ever been hospitalised due to asthma (e.g. intensive care unit).
Participants with asthma that have received treatment with oral corticosteroids/been admitted to hospital during the past 12 months for their asthma.
An increase/step-up in asthma medication during the study (e.g. moving from Step 1 to Step 2, Step 2 to Step 3 etc.).
Participants with asthma who do not obtain an additional prescription for a reliever inhaler to be stored securely at NTU if needed during visits. Additional prescriptions must be obtained before familiarisation/visit two. Participants will be reimbursed for the cost of additional reliever inhaler prescriptions.
History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease.
History of recurrent chest infections.
Smoker.
Pregnant, planning pregnancy or lactating.
Had an acute infection in the last four weeks, and/or major operation in the past four months.
History of gastrointestinal drug reaction.
Have taken antibiotics in the past 3 months.
History or current evidence of gastrointestinal disease (e.g. chronic constipation, diarrhoea, irritable bowel syndrome, Chrohn's disease).
Have recently taken part in other research projects. Participants will be asked to notify the chief investigator.
Participants are, or believe that they are lactose intolerant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HOST-DM059 (Prebiotic)
HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics.
HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g.
The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum).
The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria.
HOST-DM059 encourages the growth and development of Bifidobacteria.
Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
|
Experimental Supplement: HOST-DM059. Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases.
Other Names:
|
PLACEBO_COMPARATOR: Maltodextrin
Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
|
Placebo Comparator: Maltodextrin.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes In Regulatory T Cell FOXP3 Expression From Baseline To Post Prebiotic Supplementation.
Time Frame: Week 0, Week 4, Week 6, Week 10 (Collected At Rest).
|
Flow Cytometric Analysis: CD4+ CD25+ IL-10+ Regulatory T Cell FOXP3 Expression (
|
Week 0, Week 4, Week 6, Week 10 (Collected At Rest).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change In Systemic Immune Function/Inflammatory Markers
Time Frame: Week 0, Week 4, Week 6, Week 10 (Blood Sample Collected At Rest).
|
Flow Cytometric Analysis: Interleukin (IL)-10, Hematopoietic Prostaglandin D Synthase Enzyme (Pathogenic Effector/Non-Pathogenic Effector TH2 Cells), CD3 (T Cells), CD25 (Regulatory T Cells), Transforming Growth Factor-Beta (TH2 Cells), Fork-Head Box Protein-3 (Regulatory T Cells), CD161 (PETH2 Cells), Interferon-Gamma (TH1 Cells), Live/Dead, Total & Specific White Blood Cell Counts (Eosinophils, Basophils, Neutrophils, Monocytes, Lymphocytes).
|
Week 0, Week 4, Week 6, Week 10 (Blood Sample Collected At Rest).
|
Change In Pulmonary Function (FEV1)
Time Frame: Week 0, Week 4, Week 6, Week 10 (At Rest & In Duplicate At 3, 6, 10, 15, 20, & 30 Minutes Post EVH).
|
% Drop In Pulmonary Function (FEV1) Post EVH = 100*(Highest Baseline FEV1-Lowest Post EVH FEV1)/Highest Baseline FEV1. Used To Objectively Diagnose Asthma/EIB (> 10% Drop In FEV1 Post EVH At Two Consecutive Time Points), And Classify Severity As Mild (> 10% - < 25% Drop In FEV1), Moderate (> 25% - < 50% Drop In FEV1), Or Severe (> 30%, Or 50% Drop In FEV1 For Patients Receiving/Not Receiving Steroid Based Treatments). All Pulmonary Function Parameters: FEV1, FVC, PEF, FEF25%-75%. > 10% Reduction = Positive Objective Diagnosis (Asthma/EIB). |
Week 0, Week 4, Week 6, Week 10 (At Rest & In Duplicate At 3, 6, 10, 15, 20, & 30 Minutes Post EVH).
|
Change In The Asthma Control Questionnaire - Perceived Symptom Management
Time Frame: Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. (Upon Experimental Trial Arrival During Weeks 0, 4, 6, & 10).
|
Common Asthma Symptoms Management: Night Time Awakening, Upon Waking Symptom Severity, Physical Activity Limitation, Dyspnoea (Breathlessness), Wheezing, Reliever Medication Usage (Rating 0-6).
|
Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. (Upon Experimental Trial Arrival During Weeks 0, 4, 6, & 10).
|
Change In Urinary Metabolite Concentrations
Time Frame: Week 0, Week 4, Week 6, Week 10 (Urine Sample) (Collected At Rest & 60 Minutes Post EVH).
|
E.G.: Acetic Acid, Propionic Acid, I-Butyric Acid, N-Butyric Acid, I-Valeric Acid, N-Valeric Acid, N-Caproic Acid.
|
Week 0, Week 4, Week 6, Week 10 (Urine Sample) (Collected At Rest & 60 Minutes Post EVH).
|
Change In The Medication Adherence Report Scale For Asthma (MARS-A)
Time Frame: Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. (Upon Experimental Trial Arrival During Weeks 0, 4, 6, & 10).
|
Asthma Medication & Nutritional Interventions Adherence Measurement (12 Questions) (Rating 1-5).
|
Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. (Upon Experimental Trial Arrival During Weeks 0, 4, 6, & 10).
|
Change In 24 Hour Weighed Nutritional Intake Record
Time Frame: Week 0, Week 4, Week 8, Week 12 (24 Hours Before Experimental Trial).
|
Quantitative Measurement - Habitual Nutritional Consumption (Assess Nutritional Intake Consistency Across Experimental Trials).
|
Week 0, Week 4, Week 8, Week 12 (24 Hours Before Experimental Trial).
|
Changes In Intestinal Permeability Markers
Time Frame: Week 0, Week 4, Week 6, Week 10 (Blood Sample Collected At Rest).
|
Blood (Serum/Plasma) Based Measurement.
|
Week 0, Week 4, Week 6, Week 10 (Blood Sample Collected At Rest).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Principal Component Analysis/Cluster Analysis - Primary/Secondary Outcome Measures
Time Frame: Post Data Collection.
|
All Relevant Meta-Data.
|
Post Data Collection.
|
Partial Least Squares Discriminant Analysis.
Time Frame: Post Data Collection.
|
Urinary Metabolite Profiles. Untargetted Metabolomics. 1H Nuclear Magnetic Resonance (NMR) Spectroscopy. |
Post Data Collection.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Graham R Sharpe, PhD, Nottingham Trent University
Publications and helpful links
General Publications
- Williams NC, Johnson MA, Hunter KA, Sharpe GR. Reproducibility of the bronchoconstrictive response to eucapnic voluntary hyperpnoea. Respir Med. 2015 Oct;109(10):1262-7. doi: 10.1016/j.rmed.2015.08.006. Epub 2015 Aug 13.
- Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, Gibson GR. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. 2015 Aug 28;114(4):586-95. doi: 10.1017/S0007114515001889. Epub 2015 Jul 28.
- Williams NC, Johnson MA, Shaw DE, Spendlove I, Vulevic J, Sharpe GR, Hunter KA. A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. Br J Nutr. 2016 Sep;116(5):798-804. doi: 10.1017/S0007114516002762.
- Hevia A, Milani C, Lopez P, Donado CD, Cuervo A, Gonzalez S, Suarez A, Turroni F, Gueimonde M, Ventura M, Sanchez B, Margolles A. Allergic Patients with Long-Term Asthma Display Low Levels of Bifidobacterium adolescentis. PLoS One. 2016 Feb 3;11(2):e0147809. doi: 10.1371/journal.pone.0147809. eCollection 2016.
- Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, Kuzeljevic B, Gold MJ, Britton HM, Lefebvre DL, Subbarao P, Mandhane P, Becker A, McNagny KM, Sears MR, Kollmann T; CHILD Study Investigators; Mohn WW, Turvey SE, Finlay BB. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015 Sep 30;7(307):307ra152. doi: 10.1126/scitranslmed.aab2271.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Asthma
- Metabolomics
- Pulmonary Function
- Regulatory T Cells
- Gut Microbiota
- Acetate
- Propionate
- Butyrate
- Prebiotics
- Airway Inflammation
- Intestinal Permeability
- Exercise-Induced Bronchoconstriction
- Nutritional Intervention
- Systemic Inflammation
- Exercise-Induced Asthma
- Gut Bacteria
- Bimuno® Galactooligosaccharide
- Eucapnic Voluntary Hyperpnoea
- Systemic Immune Function
- TH1 Cells
- TH2 Cells
- Short-Chain Fatty Acids
Additional Relevant MeSH Terms
Other Study ID Numbers
- 233556
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on HOST-DM059
-
Duke UniversityAntibacterial Resistance Leadership GroupCompletedBacterial Infections | Virus Disease | Respiratory Tract Infection Acute | TranscriptomeUnited States
-
University of SienaFondazione Policlinico Universitario Agostino Gemelli IRCCS; Istituti Ospitalieri... and other collaboratorsRecruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedGraft Versus Host Disease | Ophthalmologic ComplicationsUnited States
-
Hadassah Medical OrganizationWithdrawnNeoplasm Metastasis | Hematological MalignancyIsrael
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Icahn School of Medicine at Mount SinaiUnknownMultiple Myeloma | Hodgkin's Disease | Chronic Lymphocytic Lymphoma | Relapsed Non-Hodgkin's LymphomaUnited States
-
Kiadis PharmaTerminatedLymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic LeukemiaCanada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Kiadis PharmaCompletedHematologic Diseases | Hematologic MalignanciesCanada
-
National Taiwan University HospitalMackay Memorial Hospital; National Cheng-Kung University Hospital; Tri-Service... and other collaboratorsRecruitingMultisystem Inflammatory Syndrome in Children | COVID-19-Associated EncephalitisTaiwan